SG Americas Securities LLC Sells 55,503 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

SG Americas Securities LLC lessened its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 22.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 197,106 shares of the biopharmaceutical company’s stock after selling 55,503 shares during the quarter. SG Americas Securities LLC owned 0.40% of Theravance Biopharma worth $2,215,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of TBPH. UBS Group AG raised its stake in shares of Theravance Biopharma by 45.0% in the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,101 shares during the last quarter. Point72 Middle East FZE bought a new stake in Theravance Biopharma during the fourth quarter worth $41,000. Tower Research Capital LLC TRC raised its position in Theravance Biopharma by 116.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,015 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 2,157 shares during the last quarter. Quantbot Technologies LP bought a new position in Theravance Biopharma during the 2nd quarter valued at $62,000. Finally, Royal Bank of Canada lifted its stake in Theravance Biopharma by 1,330.7% during the 3rd quarter. Royal Bank of Canada now owns 6,610 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 6,148 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Evercore ISI lowered shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a research note on Monday, January 8th.

Theravance Biopharma Stock Up 2.2 %

Shares of NASDAQ TBPH opened at $9.01 on Thursday. The company has a market capitalization of $434.01 million, a PE ratio of -9.29 and a beta of 0.36. The stock’s 50 day moving average price is $9.01 and its 200-day moving average price is $9.65. Theravance Biopharma, Inc. has a twelve month low of $8.21 and a twelve month high of $12.03.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Theravance Biopharma had a negative return on equity of 19.31% and a negative net margin of 96.12%. The business had revenue of $17.57 million during the quarter, compared to analysts’ expectations of $17.49 million. As a group, research analysts expect that Theravance Biopharma, Inc. will post -0.83 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.